Glucokinase activator compositions for the treatment of diabetes
The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
1. A method of increasing insulin sensitivity in a mammal having type II diabetes comprising administering to the mammal a therapeutically effective amount of a liver-selective glucokinase activator in combination with a therapeutically effective amount of a GLP-1 analog or a pharmaceutically acceptable salt thereof, wherein insulin sensitivity in the mammal is increased.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the liver-selective glucokinase activator and the GLP-1 analog are administered in discrete dosage forms.
4. The method of claim 1 , wherein the liver-selective glucokinase activator and the GLP-1 analog are administered in a single dosage form.
5. The method of claim 1 , wherein the GLP-1 analog is administered by injection and the liver-selective glucokinase activator is administered orally.
6. The method of claim 1 , wherein the GLP-1 analog is exenatide or a pharmaceutically acceptable salt thereof.
7. A method of improving glycemic control in a mammal having impaired glucose metabolism by increasing a mammal's insulin sensitivity comprising administering to the mammal a therapeutically effective amount of a liver-selective glucokinase activator in combination with a therapeutically effective amount of GLP-1 analog or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , wherein the mammal is a human.
9. The method of claim 7 , wherein the liver-selective glucokinase activator and the GLP-1 analog are administered in discrete dosage forms.
10. The method of claim 7 , wherein the liver-selective glucokinase activator and the GLP-1 analog are administered in a single dosage form.
11. The method of claim 7 , wherein the GLP-1 analog is administered by injection and the liver-selective glucokinase activator is administered orally.
12. The method of claim 7 , wherein the GLP-1 analog is exenatide or a pharmaceutically acceptable salt thereof.